Inhibition of chronic and acute skin inflammation by treatment with a vascular endothelial growth factor receptor tyrosine kinase inhibitor
about
Vascular endothelial growth factor inhibitors: investigational therapies for the treatment of psoriasisLymphatic vascular response to acute inflammationCollared mice: a model to assess the effects of scratchingInhibition of neovascularization to simultaneously ameliorate graft-vs-host disease and decrease tumor growthVascular pathology in multiple sclerosis: mind boosting or myth busting?Interplay between Inflammatory Responses and Lymphatic Vessels.Stimulation of lymphangiogenesis via VEGFR-3 inhibits chronic skin inflammation.Tyrosine kinases in inflammatory dermatologic disease.Halting angiogenesis by non-viral somatic gene therapy alleviates psoriasis and murine psoriasiform skin lesions.Role of VEGF receptors in normal and psoriatic human keratinocytes: evidence from irradiation with different UV sources.Double anti-angiogenic and anti-inflammatory protein Valpha targeting VEGF-A and TNF-alpha in retinopathy and psoriasis.An important role of the SDF-1/CXCR4 axis in chronic skin inflammationInvolvement of corneal lymphangiogenesis in a mouse model of allergic eye diseaseThe cutaneous vascular system in chronic skin inflammationAn important role of blood and lymphatic vessels in inflammation and allergy.Bimodal Expansion of the Lymphatic Vessels Is Regulated by the Sequential Expression of IL-7 and Lymphotoxin α1β2 in Newly Formed Tertiary Lymphoid Structures.Systemic anti-VEGF treatment strongly reduces skin inflammation in a mouse model of psoriasis.The role of angiogenesis in the pathogenesis of psoriasis.Vitamin D inhibits lymphangiogenesis through VDR-dependent mechanisms.Investigational VEGF antagonists for psoriasis.Psoriasis drug discovery: methods for evaluation of potential drug candidates.Ultraviolet light-induced changes of lymphatic and blood vasculature in skin and their molecular mechanisms.Two cases of psoriasis responding to erlotinib: time to revisiting inhibition of epidermal growth factor receptor in psoriasis therapy?.The inflammatory response of lymphatic endothelium.Lymphangiogenic factors, mechanisms, and applications.VEGF Pathways in the Lymphatics of Healthy and Diseased Heart.Novel investigational vascular endothelial growth factor (VEGF) receptor antagonists for psoriasis.Nanoemulsion is an effective antimicrobial for methicillin-resistant Staphylococcus aureus in infected wounds.Conditioned media from hypoxic-cultured human dental pulp cells promotes bone healing during distraction osteogenesis.Intralesional Bevacizumab (Avastin®) as a Novel Addition to Infantile Hemangioma Management: A Medical Hypothesis.Molecular pathophysiology of psoriasis and molecular targets of antipsoriatic therapy.
P2860
Q22305863-D4631264-162B-4D89-82E5-43641E208C03Q27304915-7B59FF23-72BC-41D8-BEDE-0226442094A5Q33637081-FC3CB624-E03A-4D6D-892C-4EC7B450EF96Q33915046-1044DC83-0AD1-4989-893C-91F3328D575AQ33960741-97EF53A1-BC98-4CB8-8F8E-DD48EEC5CFC6Q34105706-AB19EB21-2616-4FFE-A62B-BD9C52B1A25FQ34161479-367F2F68-103C-4074-BF70-557558982847Q34166503-A587892F-56F7-4C5A-BFF3-1008B4ACE60FQ34428875-5C2A774B-D666-444F-BBE6-47E4D5B2677EQ34576604-414A5662-4F2F-4B6D-B88F-2F59FD14D0ABQ34800330-8D3B23E7-05C6-4D22-B15F-65EECC21F3E8Q35138679-11D18159-0D34-4128-845A-A47E2E3DD739Q35672575-E7E932D3-9BEA-43DA-A6DA-2C1706278896Q36098582-516A4F82-D1B0-458C-86BA-B045993D4F31Q36616466-A59DD1A6-4CAC-476B-8865-C29F6D677E45Q37189681-FC127112-7EE5-4F76-AF30-3F2A75973D5CQ37482178-486CB9C1-9ED1-4CB4-A43D-EAEA88C9FC2CQ37622941-D6A59ECF-1A77-49A9-9A8F-01B17A843BE0Q37707913-74DD47E1-26A7-4AC6-893F-47FADA8FD24DQ37956733-5BE6F960-A998-4402-AD26-A2DF5677D114Q37999088-EAB9DB04-A9F0-4F06-B5BD-420E38105218Q38012875-DBD96811-D739-4B01-BF6A-968D6540C31BQ38055311-775F73C1-39EB-4695-9E23-A4C04281DF3CQ38155100-793BEC56-CC6E-48E0-A554-1ABC6BFF4D30Q38192927-DD9433C2-0D50-4FCC-9639-08B1AB834705Q38550432-A57B7E57-BC1A-44AA-9987-F691BF60A405Q38728552-F41924A8-6FB0-44EB-A5C7-053C813226B7Q40235599-8B57956E-A067-4374-B794-7A0F9C94D08EQ41052501-F824F0FC-5A38-4300-A518-4D144282A941Q42269844-695DD750-EE12-4430-A1AF-493BD290CD01Q50590488-D83ECF2C-D20D-4F9A-A481-0B1EFDA61F31
P2860
Inhibition of chronic and acute skin inflammation by treatment with a vascular endothelial growth factor receptor tyrosine kinase inhibitor
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Inhibition of chronic and acut ...... ptor tyrosine kinase inhibitor
@ast
Inhibition of chronic and acut ...... ptor tyrosine kinase inhibitor
@en
type
label
Inhibition of chronic and acut ...... ptor tyrosine kinase inhibitor
@ast
Inhibition of chronic and acut ...... ptor tyrosine kinase inhibitor
@en
prefLabel
Inhibition of chronic and acut ...... ptor tyrosine kinase inhibitor
@ast
Inhibition of chronic and acut ...... ptor tyrosine kinase inhibitor
@en
P2093
P2860
P1476
Inhibition of chronic and acut ...... ptor tyrosine kinase inhibitor
@en
P2093
Amanda Littlewood-Evans
Anton Stuetz
Cornelia Halin
Guido Bold
Hermann Fahrngruber
Josef G Meingassner
P2860
P304
P356
10.2353/AJPATH.2008.071074
P407
P577
2008-06-05T00:00:00Z